Tokyo-based Meiji Seika Pharma has received approval in Japan to produce the world’s first self-amplifying mRNA COVID-19 vaccine without safety data.
The world's first COVID-19 self-amplifying mRNA (sa-mRNA) vaccine has been authorized in Japan; however, the vaccine's maker has not released any safety or effectiveness information.
In a press statement on November 28, Tokyo-based Meiji Seika Pharma stated that it has acquired approval to begin producing and selling its Kostaive sa-mRNA COVID-19 vaccine. When the vaccine's mRNA enters cells, it is intended to self-amplify, resulting in a “strong immune response and the potential for extended duration of protection.” The adult population is meant to receive both booster shots and two doses of the main vaccination from this vaccine. According to the press release, Kostaive is the "world's first approved product applying self-amplifying mRNA technology."
RNA vaccinations that use a virus's genetic code against it are known as ...